- Home
- ALV vs BPMC Comparison
ALV vs BPMC Comparison
Compare ALV & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- BPMC
- Stock Information
- Founded
- ALV 1953
- BPMC 2008
- Country
- ALV Sweden
- BPMC United States
- Employees
- ALV N/A
- BPMC N/A
- Industry
- ALV Auto Parts:O.E.M.
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- BPMC Health Care
- Exchange
- ALV Nasdaq
- BPMC Nasdaq
- Market Cap
- ALV 7.2B
- BPMC 5.8B
- IPO Year
- ALV 1997
- BPMC 2015
- Fundamental
- Price
- ALV $102.70
- BPMC $127.60
- Analyst Decision
- ALV Buy
- BPMC Buy
- Analyst Count
- ALV 11
- BPMC 19
- Target Price
- ALV $114.64
- BPMC $124.75
- AVG Volume (30 Days)
- ALV 511.7K
- BPMC 3.8M
- Earning Date
- ALV 07-18-2025
- BPMC 07-31-2025
- Dividend Yield
- ALV 2.72%
- BPMC N/A
- EPS Growth
- ALV 35.84
- BPMC N/A
- EPS
- ALV 8.68
- BPMC N/A
- Revenue
- ALV $10,353,000,000.00
- BPMC $562,121,000.00
- Revenue This Year
- ALV N/A
- BPMC $44.34
- Revenue Next Year
- ALV $3.78
- BPMC $32.56
- P/E Ratio
- ALV $11.67
- BPMC N/A
- Revenue Growth
- ALV N/A
- BPMC 99.19
- 52 Week Low
- ALV $75.49
- BPMC $73.04
- 52 Week High
- ALV $128.66
- BPMC $128.15
- Technical
- Relative Strength Index (RSI)
- ALV 62.09
- BPMC 76.27
- Support Level
- ALV $100.75
- BPMC $94.38
- Resistance Level
- ALV $105.60
- BPMC $128.15
- Average True Range (ATR)
- ALV 1.55
- BPMC 3.38
- MACD
- ALV -0.27
- BPMC 2.27
- Stochastic Oscillator
- ALV 59.44
- BPMC 98.37
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.